NCT00035529View on ClinicalTrials.gov

A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-remitting Multiple Sclerosis

PHASE2TerminatedINTERVENTIONAL
Timeline

Start Date

November 30, 2001

Primary Completion Date

December 31, 2003

Study Completion Date

December 31, 2003

Conditions
Multiple Sclerosis
Interventions
DRUG

Placebo

Solution, i.v infusion, 0 mg, Days 1 \& 15 then monthly, 10 months.

DRUG

BMS 188667 (Abatacept)

Vial, i.v infusion, 2mg/kg, Days 1 \& 15 then monthly, 10 months.

DRUG

BMS 188667 (Abatacept)

Vial, i.v infusion, 10 mg/kg, Days 1 \& 15 then monthly, 10 months.

Trial Locations (10)

Unknown

Local Institution, New Haven

Local Institution, Louisville

Local Institution, Worcester

Local Institution, Newark

Local Institution, New York

Local Institution, Charlotte

Local Institution, Philadelphia

Local Institution, Dallas

Local Institution, Burlington

Local Institution, Madison

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT00035529 - A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-remitting Multiple Sclerosis | Biotech Hunter | Biotech Hunter